UNSPSC 51113103: Mitolactol

This classification denotes a radiosensitizing agent and epoxide compound with the molecular formula C6H12Br2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LJ2P1SIK8Y, chemically known as 1,6-dideoy-1,6-dibromo-d-mannitol but more generally known as mitolactol, which bears US NIH Compound Identifier 4208. European Medicines Agency schedules Mitolactol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09005MIG.

UNSPSC 51113103 Mitolactol is a Commodity code representing a single pharmaceutical product actively procured by state health authorities. The Texas Health and Human Services Commission (HHS) is currently evaluating direct-to-manufacturer prescription supply channels for mitolactol and related pharmaceuticals through its Therapeutic Pharmacy Initiative (TPI), seeking to establish supply relationships that bypass traditional pharmacy benefit managers, group purchasing organizations, and wholesalers. The state is soliciting vendor capacity to deliver products directly under negotiated net pricing models, implement value-based or outcomes-based agreements, and fulfill volume requirements through dedicated pharmacy partners or specialized distribution channels. This procurement activity reflects state purchasing interest in direct pharmaceutical sourcing to improve fulfillment efficiency and manage costs within state employee and retiree health plans as well as self-insured government health programs.

The geographic activity is concentrated in Texas, where the HHS Commission issued a Request for Information (RFI) numbered HHS0017013 on April 3, 2026, with a response deadline of the same date. The RFI is an exploratory market-intelligence exercise intended to inform the state's future formal solicitation strategy and program design rather than a binding competitive opportunity; no award value, budget ceiling, or set-aside designations are identified at this stage. Upon completion of vendor responses, Texas HHS intends to develop detailed procurement specifications, pricing models, and implementation timelines for a subsequent formal Request for Proposal (RFP).